Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

of less than 70 mg/dL. For Moderately High-Risk patients, the target is less than 130 mg/dL. Over 20 million people in the U.S. in the High-Risk and Moderately High-Risk categories are failing to meet recommended LDL-C targets using currently available lipid-lowering therapies.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of ISIS 301012 in treating high cholesterol. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a b
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/27/2015)... May 27, 2015 ... the addition of the  "2015 Strategies in ...  report to their offering.       ... report contains 500 pages, 120 tables, and ... potential market entrants identify and evaluate business ...
(Date:5/27/2015)... OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts ... a series of diverse complications arising from the presence ... tissues, which cause a rapidly progressing hyperactive host immune ... 50% depending on disease severity. The syndrome places a ... global marketplace, which for the purposes of this report ...
(Date:5/27/2015)... May 27, 2015 PharmaPoint: Type 1 Diabetes - ... Type 1 diabetes (T1D) is an autoimmune disease that ... that the body can no longer produce insulin. Over the ... at present, no other treatment can be offered to a ... insulin analogs with different times of action - long-acting as ...
Breaking Medicine Technology:European Hemostasis Diagnostic Testing Market Strategies 2015 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4
... , SALT LAKE CITY , March 15 Otix Global, Inc. (Nasdaq: OTIX ), announced today that it ... to April 11, 2011 , modifies covenants, and revises the borrowing base formula which allows the Company to obtain additional funds ... ... , ...
... March 14 Siemens Healthcare addresses the ... 59th Annual Scientific Session of the American College of Cardiology ... booth #1018. With a commitment to excellence, Siemens empowers its ... world of cardiology, and help them meet their strategic and ...
Cached Medicine Technology:Otix Global, Inc. Extends Term of Loan and Security Agreement With Silicon Valley Bank 2Otix Global, Inc. Extends Term of Loan and Security Agreement With Silicon Valley Bank 3Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 2Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 3Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 4Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 5Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 6Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 7Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 8Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 9Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 10Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 11Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 12Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 13Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 14
(Date:5/27/2015)... 2015 Ticket Down is a reputable source for ... have been super hot during the 2014-15 NBA season and they ... with a final score of 118-88. , For the ... since 2006-2007 when they lost to the San Antonio Spurs. ... of the Cavaliers making it to the NBA finals increased tenfold. ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 The BBB ... customer service practices that enhance customer trust and confidence ... Standards for Trust, eight principles that summarize important elements ... also represents standards for business accreditation by BBB. Businesses ... these standards and complete application procedures will be accredited ...
(Date:5/27/2015)... “ Nursing Homes are starting to supplant hospitals ... of a recent April 2015 New York Times article. While ... the hospital, 20-plus years of research have documented the risks ... nursing homes are both safer for older patients and less ... homes varying widely, patients and family members may worry whether ...
(Date:5/27/2015)... Continuing its commitment to finding a cure ... community, SmartPractice® donated $25,000 to HonorHealth Breast ... Vice President of Human Resources Meg Mosher and SmartScrubs ... to Paulla Miller, Sherry Gage, Dr. Linda Greer and ... on April 30. The center is located at 19646 ...
(Date:5/27/2015)... May 27, 2015 While hair transplantation ... loss, a new pilot study conducted by a physician ... (ISHRS) has found hair follicle grafting can help treat ... was partially funded by ISHRS, which offers research grants ... hair restoration. , In the past decade, numerous ...
Breaking Medicine News(10 mins):Health News:Cavs NBA Finals Tickets: Ticket Down Slashes Ticket Prices on Cleveland Cavaliers 2015 NBA Finals Tickets at Quicken Loans Arena and Offers Valuable Promo Code 2Health News:Carson Energy Receives A+ Accredited Rating For 19 Consecutive Years 2Health News:BestNursingHomes.com Launches on National Senior Health and Fitness Day 2Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3
... , FRIDAY, June 10 (HealthDay News) -- People ... on the appearance of their office, research suggests. ... photographs of offices belonging to actual psychotherapists in Manhattan. ... for quality and qualifications to psychotherapists whose offices were ...
... -- People have a difficult time ignoring objects that ... could help lead to new treatments for addiction, obesity ... A team of neuroscientists at Johns Hopkins University ... visual search task were distracted when they saw items ...
... Clinically ascertained reports suggest that boys and girls with ... other in their vulnerability to substance use problems, say ... of Jyvskyl, Finland. A total of 1545 ... their parents and classroom teachers using standardized rating scales ...
... Although liver-related mortality among those infected with hepatitis ... in these patients that are not related to ... Clinical Infectious Diseases and now available online ... all causes, including liver- and non-liver related deaths ...
... News) -- Some patients with advanced cancer receive drugs ... a U.S. study suggests. University of Chicago researchers ... metastatic colon cancer who were treated between January 2007 ... eight received chemotherapy treatments that weren,t supported by evidence ...
... THURSDAY, June 9 (HealthDay News) -- Although nearly all American ... parents express concerns about the shots, and a small number ... Centers for Disease Control and Prevention. About 95 percent ... or would get them all, which was a record high, ...
Cached Medicine News:Health News:Psychotherapists With Tidy Offices Seen as More Competent 2Health News:Some Brains Easily Distracted by Rewarding Stimuli 2Health News:Analysis finds mortality from all causes higher among hepatitis C-infected 2Health News:Chemo for Late-Stage Cancer Patients May Be Unjustified 2Health News:Most U.S. Kids Get Recommended Vaccines: CDC 2Health News:Most U.S. Kids Get Recommended Vaccines: CDC 3
Calss II Type B2 Biological Safety Cabinet...
Inquire...
... Built-in, motor-driven internal calibration mass ... Also capable of Fully Automatic ... when temperature changes are detected, ... weights. Built-in RS232 Interface, Shimadzu ...
60 month warranty; Internal Calibration Mass System Diagnostic to alert operator of abnormal weighing conditions; built-in motorized calibration weight enabling automatic self calibration....
Medicine Products: